Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 118   

Articles published

JNJ 101.22 +0.86 (0.86%)
price chart
Johnson & Johnson to Begin Testing Ebola Vaccine in January
Johnson & Johnson said it would begin testing an Ebola-virus vaccine in humans in January and could have 250,000 doses available in May, if health authorities deem it safe and promising enough to distribute more broadly.
Testing for Ebola Vaccines to Start Soon, WHO Says  New York Times
Related articles »  
Johnson & Johnson Plans Ebola Vaccine Testing
Johnson & Johnson will begin safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus.
Why Johnson & Johnson (JNJ) Stock Is Higher Today  TheStreet.com
Related articles »  
Ebola: Johnson & Johnson to start vaccine trials in January
Johnson & Johnson is to start testing its Ebola vaccine candidate in January after the World Health Organisation (WHO) and world leaders asked it and other companies to accelerate their research programmes.
AOL.com Article - Johnson & Johnson plans Ebola vaccine testing
NEW BRUNSWICK, N.J. (AP) - Johnson & Johnson will begin safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus.
Johnson & Johnson accelerates Ebola vaccine testing amid heightened anxiety
"We are urgently working to provide our vaccine expertise, production capabilities, our people and resources to address the Ebola crisis," said Alex Gorsky, Chairman and CEO of Johnson & Johnson." Our innovation model enables us to quickly mobilize our ...
Is Johnson & Johnson's Worst Nightmare Becoming Reality?
Johnson & Johnson (NYSE: JNJ ) has been one of the few top healthcare companies to post strong growth within its pharmaceutical segment this year.
Related articles »  
Johnson & Johnson to Buy Biotech Company Alios BioPharma
The deal has been approved by the boards of both companies, and is the first acquisition in some time for Johnson & Johnson, which has been more focused on selling assets than buying them this year. In March, Johnson & Johnson sold its K-Y brand of ...
Johnson & Johnson Buying Alios for $1.75B  ABC News
What Johnson & Johnson's Alios Acquisition Means for Gilead Sciences  Barron's (blog)
Related articles »  
Market Reaction To Johnson & Johnson's Earnings Is Justified
Johnson & Johnson's stock price fell sightly following its Q3 2014 earnings announcement despite the company beating consensus estimates and keeping the full year outlook the same.
Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine ...
NEW BRUNSWICK, N.J., Oct. 22, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in ...
Johnson & Johnson to invest $200M in Ebola vaccine testing
Johnson & Johnson will begin safety testing in early January on a two-step vaccine that it hopes could protect people from a strain of the deadly Ebola virus.